Tag Archives: PK/PD

Efficacy and Treatment Duration: Where is the Tipping Point?

Posted on by — No Comments ↓

Development pf antibacterials differs in several important ways from drug development in other areas, and the lack of standard dose-finding is just one of them. Dose-finding in its most basic form involves ascending amounts of drug for efficacy and safety; for antibiotics, however, an effective dose can be predicted nowadays Continue reading Efficacy and Treatment Duration: Where is the Tipping Point?→

Timely New Information on Next-Generation Tetracyclines – Part 2: Eravacycline and Protein Binding

Posted on by — 2 Comments ↓

A recent paper by Thabit describes a curious finding [1]. The authors measured total and free (i.e., nonprotein-bound) eravacycline levels at ascending doses in a mouse model. They found strikingly small increases in free drug levels when titrating up total doses. The effect was rather dramatic: an increase in protein binding from 12% Continue reading Timely New Information on Next-Generation Tetracyclines – Part 2: Eravacycline and Protein Binding→

Eravacycline Conference Call: Unrevealing and Disappointing

Posted on by — No Comments ↓

Whatever has become of investigative journalism?  All we read after the Stifel conference call (11/17/2015) is descriptive rehash of information provided by Tetraphase at the conference.  No probing questions that we thought investors would ask who just lost 80% of their money.  No signs of analytical or strategic readjustment at Continue reading Eravacycline Conference Call: Unrevealing and Disappointing→